Author

S. Z. Lam

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Bioengineering· 2 Immunology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Research Focus:drug response / drug discovery· 3 Research Focus:cell type annotation· 2 Research Focus:gene regulatory network inference· 2 Approach:genetic perturbation / CRISPR· 2 Organism:mouse· 2 Research Focus:cancer & tumor microenvironment· 1 Assay:CRISPR screen· 1 Approach:deep learning· 1

Frequent Co-Authors

S. Chen· 3 shared L. Peng· 2 shared L. Yang· 2 shared L. Ye· 2 shared Q. Lin· 2 shared Y. Zhang· 2 shared A. Du· 1 shared A. Sanchez· 1 shared

Activity by Year

2023-2024 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 27 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

3 shared papersBioengineering

S. Chen

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

High-fidelity enhanced AsCas12a knock-in mice for efficient multiplexed gene editing, disease modeling and orthogonal immunogenetics

K. Tang, X. Zhou, S.-Y. Fang, E. Vandenbulcke, A. Du, J. Shen, H. Cao, J. Zhou, K. Chen, S. Xin, L. Zhou, S. H. Lin, M. Majety, X. Ling, S. Z. Lam, , S. Chen

bioRxiv · Mar 14, 2024 · PreprintBioengineering

Perturbomics of tumor-infiltrating NK cells

L. Peng, P. A. Renauer, L. Ye, L. Yang, J. J. Park, R. D. Chow, Y. Zhang, Q. Lin, M. Bai, A. Sanchez, Y. Zhang, S. Z. Lam, S. Chen

This study identifies genetic factors limiting NK cell function in tumors using CRISPR screens and single-cell sequencing, highlighting CALHM2 as a target for improving NK cell-based therapies.

bioRxiv · Mar 14, 2023 · PreprintImmunology

Therapeutic immune cell engineering with an mRNA : AAV-Sleeping Beauty composite system

L. Ye, S. Z. Lam, L. Yang, K. Suzuki, Y. Zou, Q. Lin, Y. Zhang, P. Clark, L. Peng, S. Chen

The paper introduces a composite gene delivery system called MAJESTIC for efficient and stable engineering of therapeutic immune cells, showing improved cell viability and transgene expression compared to existing methods.

bioRxiv · Mar 14, 2023 · PreprintBioengineering